Cargando…
A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma
Enhancer DNA methylation and expression of MYBPHL was studied in multiple myeloma (MM). By bisulfite genomic sequencing, among the three CpGs inside the MYBPHL enhancer, CpG1 was significantly hypomethylated in MM cell lines (6.7–50.0%) than normal plasma cells (37.5–75.0%) (P = 0.007), which was ne...
Autores principales: | Wong, Kwan Yeung, Morgan, Gareth J., Boyle, Eileen M., Cheng, Alfred Sze Lok, Yip, Kevin Yuk-Lap, Chim, Chor Sang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997988/ https://www.ncbi.nlm.nih.gov/pubmed/33772052 http://dx.doi.org/10.1038/s41598-021-86473-y |
Ejemplares similares
-
Myosin binding protein H-like (MYBPHL): a promising biomarker to predict atrial damage
por: Lahm, Harald, et al.
Publicado: (2019) -
Epigenetic silencing of LPP/miR-28 in multiple myeloma
por: Li, Zhenhai, et al.
Publicado: (2018) -
Central and peripheral pathogenetic forms of type 2 diabetes: a proof-of-concept study
por: Davydov, Dmitry M, et al.
Publicado: (2016) -
Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
por: Wong, Kwan Yeung, et al.
Publicado: (2013) -
High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes
por: Bai, Yinlei, et al.
Publicado: (2016)